Attenuation of the pressor response to exogenous angiotensin by angiotensin receptor blockers and benazepril hydrochloride in clinically normal cats

Abstract

Results indicated that telmisartan administration may have advantages over benazepril administration for cats with renal or cardiovascular disease.

Attenuation of the blood pressure response to exogenous angiotensin I after oral administration of benazepril to healthy adult horses

“…In addition, the mean ΔSBP of 38.8 ± 3.7 mmHg, obtained in this study prior to administration of benazepril, was slightly higher than the 20–30 mmHg target used in man. A study in cats has shown that I max is inversely correlated to both the dose of ANG‐I used and resulting ΔSBP . Therefore, the slightly higher than optimal dose of ANG‐I used in this study might have contributed to the inability to achieve target I max despite the documented high levels of serum ACE inhibition.…”

ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats

“…Telmisartan is an ARB currently licensed in Europe for the treatment of feline proteinuria due to CKD . Initial studies in healthy anesthetized cats undergoing radiotelemetric BP monitoring, telmisartan, but not losartan, significantly attenuated the pressor response to angiotensin I . Attenuation of the SBP rise was significantly higher than for benazepril when telmisartan was administered at a higher than currently licensed dosage (3 mg/kg PO q24h) .…”

“…Initial studies in healthy anesthetized cats undergoing radiotelemetric BP monitoring, telmisartan, but not losartan, significantly attenuated the pressor response to angiotensin I . Attenuation of the SBP rise was significantly higher than for benazepril when telmisartan was administered at a higher than currently licensed dosage (3 mg/kg PO q24h) . More recently, a double‐blinded, randomized, placebo‐controlled clinical trial has explored the use of telmisartan administered at a dosage of 2 mg/kg/day for the treatment of naturally occurring hypertension in cats .…”

Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial

“…Telmisartan is a nonpeptide ARB used for the control of HT and cardiovascular protection in human patients. In a preclinical study of healthy cats, telmisartan more effectively attenuated the angiotensin I‐induced increase in systolic arterial blood pressure (SBP) than did benazepril, losartan, irbesartan, and placebo, suggesting a potential advantage for the treatment of cardiovascular and renal diseases in this species . In a separate study, telmisartan treatment was associated with measurable decreases in indirectly measured SBP in awake, unstimulated cats .…”